Search the Newsreel

Calumet (CLMT) Beat Second Quarter Estimates, Is The Stock Already Expensive?

Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals (IONS) has drawn investor attention after recent share price moves, with the stock up over the past month but down over the past …

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at …

Everyone's Watching Oklo and NuScale for Nuclear Exposure. This Overlooked Stock Is Building One Too.

The AI-driven nuclear power resurgence has been one of the hottest storylines over the past year. It has driven significant interest in nuclear energy stocks. Nuclear names like Oklo (NYSE: OKLO) and NuScale (NYSE: SMR) have been hot commodities as investors buy into the …

Eton Pharmaceuticals Stock Soars After Huge Q2 Beat And Target Hikes

Eton Pharmaceuticals (ETON) stock surged by 45.78% after reporting a significant Q2 beat, with non-GAAP EPS of $0.43 and revenue of $37.6M, driven by 99% year-over-year growth. The company also raised its 2026 revenue guidance to over $145M and adjusted EBITDA margin to at …

CCORF Maintains Orthofix Medical(OFIX.US) With Buy Rating, Maintains Target Price $13

CCORF has reiterated its Buy rating for Orthofix Medical (OFIX.US), maintaining a target price of $13. This indicates a continued positive outlook on the company's stock performance by the firm.

Enterprise value to revenue forward of Tiande Chemical Holdings Limited – HKEX:609

Eton Pharmaceuticals Soars After Blowout Q2 And Guidance Hike

Eton Pharmaceuticals (NASDAQ: ETON) experienced a significant stock surge of over 45% after reporting blowout Q2 earnings and raising its 2026 revenue guidance. The company's Q2 non-GAAP EPS and revenue significantly beat consensus estimates, driven by strong growth and the successful relaunch of Hemangeol. …

Will Aurinia’s Reaffirmed 2026 Guidance and Large Buyback Reshape Aurinia Pharmaceuticals' (AUPH) Narrative?

How Zacks’ Earnings Upgrade At Air Products (APD) Has Changed Its Investment Story

Acumen Pharmaceuticals Inc (ABOS) Stock News Today

Don't Ignore The Insider Selling In Rocket Pharmaceuticals

A Chief Operating Officer at Rocket Pharmaceuticals recently sold US$128k worth of shares, representing 6.8% of their holding. This sale was the largest insider sale in the past year, though it occurred around the current market price, making it less concerning than sales at …

Q1 2026 ICU Medical Inc Earnings Call Transcript

This article provides the edited transcript of ICU Medical Inc.'s Q1 2026 earnings call, which took place on May 7, 2026. The call began with an introduction from an unidentifiable speaker, followed by Thompson from ICR who welcomed participants to discuss the financial results. …

Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move?

Xenon Pharmaceuticals Independent Director Steven Gannon Sells 84% Of Holding

Summit Global Investments Acquires Shares of 7,182 Vertex Pharmaceuticals Incorporated $VRTX

Summit Global Investments purchased 7,182 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in the second quarter, valued at approximately $3.57 million. Other hedge funds also adjusted their holdings, with institutional investors now owning 90.96% of the stock. Analysts currently have a "Moderate Buy" rating for VRTX …

7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments

Summit Global Investments acquired 7,506 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) valued at $4.68 million during the second quarter. Regeneron reported strong quarterly results, beating analyst estimates with $14.29 EPS and $4.29 billion in revenue, representing a 16.7% year-over-year increase. Despite a "Moderate Buy" consensus …

Merit Medical Systems Eyes New Long-Range Plan as Growth, Margins Gain Momentum

Merit Medical Systems (MMSI) is developing a new long-range plan, building on recent revenue and margin growth under new CEO Martha. The company has reorganized its reporting structure into Foundational and Therapeutic product categories and is focusing on disciplined M&A to deepen existing market …

Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock

An officer at Rhythm Pharmaceuticals (RYTM.US) recently sold a substantial amount of common stock, totaling US$8.9 million. This transaction indicates a significant insider sale for the company.

Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP

Walleye Capital LLC has acquired a new position in ANI Pharmaceuticals, purchasing 106,112 shares valued at approximately $8.8 million, indicating growing institutional interest as hedge funds and other investors collectively own 76.05% of the company. ANI Pharmaceuticals recently surpassed quarterly earnings expectations, reporting adjusted …

Trifecta Capital Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Trifecta Capital Advisors LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 16,745 shares valued at approximately $8.318 million, making it their 27th largest holding. Other institutional investors like Capital Research Global Investors and State Street Corp also increased their stakes. This …

Oppenheimer Asset Management Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

Oppenheimer Asset Management Inc. has acquired a new stake of 17,931 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $8.91 million during the second quarter. This new investment comes as other institutional investors have also adjusted their holdings in VRTX. Vertex Pharmaceuticals reported earnings …

86,249 Shares in Eton Pharmaceuticals, Inc. $ETON Acquired by Walleye Capital LLC

Walleye Capital LLC has acquired 86,249 shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the second quarter, valued at approximately $3.12 million, representing a 0.31% stake in the company. This acquisition comes as Eton Pharmaceuticals reported strong quarterly results, exceeding revenue and EPS expectations, and …

Northstar Group Inc. Makes New $1.14 Million Investment in Escalade, Incorporated $ESCA

Northstar Group Inc. has made a new investment of $1.14 million in Escalade, Incorporated (NASDAQ:ESCA), acquiring 60,500 shares. This investment gives Northstar Group a 0.44% stake in the company, with institutional investors collectively owning 65.22% of Escalade. The news comes after Escalade reported strong …

Quantinno Capital Management LP Buys 24,878 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Quantinno Capital Management LP significantly increased its stake in Crinetics Pharmaceuticals, Inc. (CRNX) by 280.9% in Q1, acquiring an additional 24,878 shares to reach a total of 33,734 shares valued at $1.225 million. This comes as Crinetics Pharmaceuticals reported strong Q1 revenues of $25.12 …

How Investors May Respond To ANI Pharmaceuticals (ANIP) Record Q2 Results And Reaffirmed 2026 Revenue Guidance

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen

Dimensional Fund Advisors LP Sells 100,721 Shares of Optical Cable Corporation $OCC

Dimensional Fund Advisors LP reduced its stake in Optical Cable Corporation (NASDAQ:OCC) by 37.5%, selling over 100,000 shares but still retaining a significant holding. This comes as the company's CFO also sold a portion of her shares. Despite a recent 7.0% stock price increase, …

Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted …

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling …

Fischer Medical Ventures consolidated net profit declines 22.02% in the June 2026 quarter

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress

Amylyx Pharmaceuticals (AMLX) stock has seen a 170.4% return over the past year, but its valuation metrics suggest it is trading at a premium. The progress of the avexitide trial, including its completed pivotal trial and potential commercial launch, supports future cash flow expectations, …

Zscaler (ZS) Could Be 5% Undervalued On AI Security Spending Push

Zscaler (ZS) is gaining attention due to increased AI-focused cybersecurity spending plans, Gartner recognition, and positive analyst commentary. While its stock has seen recent volatility, Simply Wall St assesses Zscaler as 4.7% undervalued with a fair value of $192.58, driven by its ability to …

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …

Merit Medical Systems, Inc. $MMSI Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Merit Medical Systems (MMSI) by 200.3% in the first quarter, now owning 17,612 shares valued at approximately $1.21 million. This comes as institutional investors collectively hold 99.66% of the stock, and analysts maintain a "Moderate …